Every 8-K that Wave Life Sciences Ltd. (WVE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow WVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WVE filings page.
Wave Life Sciences reported financial results for the quarter ended June 30, 2026. Revenue was $2,272 thousand and the net loss was $69,355 thousand, or $0.34 per basic and diluted share, as research and development plus general and administrative expenses totaled $76,074 thousand. For the first half of 2026, revenue reached $40,518 thousand with a net loss of $95,442 thousand.
The company highlighted progress across its RNA medicines pipeline. Dosing is underway in the Phase 2a multidose INLIGHT trial of obesity candidate WVE-007, and Phase 2 combination and post-incretin maintenance trials are described as on track to initiate in the second half of 2026. In alpha-1 antitrypsin deficiency, an FDA meeting is scheduled for the end of summer 2026 to discuss a potential accelerated approval pathway for RNA editing candidate WVE-006. A clinical trial application submission for liver disease program WVE-008 is described as on track for the second half of 2026. Management characterizes the company as well capitalized, citing $490.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, with an expected cash runway into the third quarter of 2028.
Wave Life Sciences Ltd. reported that its shareholders approved a court-supervised Scheme of Arrangement needed to complete the company’s redomiciliation. At a special meeting on June 22, 2026, 87 Scheme Shareholders voted, with all 87 voting in favor and none against.
These holders cast 155,190,836 shares for the Wave Redomiciliation Proposal and 78,429 shares against, for a total of 155,269,265 shares voted. The company will now apply to the Singapore High Court for approval of the Scheme of Arrangement and, if granted, expects the redomiciliation to take effect in mid‑2026.
Wave Life Sciences reported a positive update from its RestorAATion-2 Phase 1b/2a trial of WVE-006 for alpha-1 antitrypsin deficiency. WVE-006, a subcutaneous RNA editing therapy, reduced harmful Z-AAT protein and restored protective M-AAT to levels resembling low-risk MZ individuals with both biweekly and monthly dosing.
In the 200 mg biweekly cohort, total AAT reached 11.9 µM and M-AAT rose to 64.4% of total, while Z-AAT fell by 71%. A 400 mg monthly regimen produced similar effects, with 13.6 µM total AAT and strong Z-AAT reductions. Three acute infections triggered rapid AAT surges, showing restored dynamic protein production.
Editing effects were sustained for at least three months after the last dose, and WVE-006 was generally well tolerated with only mild to moderate adverse events and no serious events or liver test issues. Wave expects mid-2026 FDA feedback on a potential accelerated approval pathway and is hosting an investor webcast to discuss the data.
Wave Life Sciences reported first quarter 2026 results and a broad pipeline update. Revenue rose to $38.2 million from $9.2 million a year earlier, while net loss narrowed to $26.1 million, or $0.13 per share, from $46.9 million.
Cash and cash equivalents were $544.6 million as of March 31, 2026, with an expected cash runway into the third quarter of 2028. The company highlighted progress for obesity candidate WVE-007, RNA editing program WVE-006 for AATD, liver disease program WVE-008, and exon 53 Duchenne therapy WVE-N531, with multiple data readouts and regulatory milestones targeted in 2026.
Wave Life Sciences Ltd. reported that its proposed redomiciliation of the group’s parent company from Singapore to the United States is progressing through the Singapore court process. The company has applied to the Singapore High Court to convene a shareholder meeting to vote on a Scheme of Arrangement under Section 210 of the Companies Act 1967.
The application, filed as case HC/OA 434/2026, is scheduled to be heard on April 29, 2026 at 10:00 am (Singapore Time). The court has set deadlines of 4:00 pm on April 22, 2026 for affidavits and 4:00 pm on April 24, 2026 for written submissions and bundles of authorities. The redomiciliation remains subject to approval by Wave shareholders and the Singapore High Court, and a definitive proxy statement with detailed information will be filed with the SEC and mailed or otherwise disseminated to shareholders.
Wave Life Sciences Ltd. plans to move its parent company domicile from Singapore to Delaware through a court-approved redomiciliation. Under a Singapore law scheme of arrangement, each existing Wave-Singapore ordinary share will be exchanged on a one-for-one basis for common stock of a new Delaware parent, Wave Life Sciences, Inc.
The new Delaware parent is expected to become the group’s ultimate holding company in mid-2026, subject to shareholder and Singapore High Court approvals, while continuing to operate the business substantially as before. The stock will keep trading on the Nasdaq Global Market under the symbol WVE, with reporting in U.S. dollars under U.S. GAAP, and the redomiciliation is expected to be tax-free to U.S. shareholders.
Wave Life Sciences reported positive interim Phase 1 data from its INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity. After six months, a single 240 mg dose produced placebo-adjusted reductions in visceral fat of -14%, total fat of -5%, waist circumference of -3%, and body weight of -1%, while lean mass increased by +2%. WVE-007 showed durable, dose-dependent suppression of serum Activin E for at least seven months, supporting the potential for once or twice-yearly dosing, and was generally safe and well tolerated up to 600 mg, with only mild or moderate adverse events.
Wave Life Sciences reported much higher cash and a larger loss for 2025 while outlining ambitious RNA programs in obesity, liver and lung disease. Cash and cash equivalents rose to $602.1 million as of December 31, 2025, giving an expected cash runway into Q3 2028.
Full-year 2025 revenue was $42.7 million, down from $108.3 million in 2024, as collaboration revenue declined. Research and development expenses increased to $182.8 million and general and administrative to $75.3 million, driving a net loss of $204.4 million versus a $97.0 million loss in 2024.
The company highlighted WVE-007 for obesity, where a single dose showed fat loss similar to GLP‑1 drugs at three months while preserving lean mass, with data updates and a Phase 2a multidose trial planned in 2026. It also advanced WVE‑006 for alpha‑1 antitrypsin deficiency, achieving total AAT levels above 11 micromolar and dynamic increases during acute phase responses, and plans a 2026 clinical trial application for WVE‑008 in PNPLA3 I148M liver disease.
Wave Life Sciences Ltd. filed a current report noting it has issued a press release titled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The company highlights regulatory plans around its WVE-006 program for this genetic condition.
The press release is furnished as Exhibit 99.1 and incorporated by reference, while a cover page interactive data file is included as Exhibit 104. The report is signed by President and Chief Executive Officer Paul B. Bolno, M.D.
Wave Life Sciences Ltd. reported a preliminary, unaudited estimate of its cash and cash equivalents, stating that this balance was approximately $602 million as of December 31, 2025. This estimate was included in a press release and an updated corporate presentation made available to the investment community.
The company emphasized that this cash figure is subject to change once full audited financial statements for the year are completed, and any adjustments could be material. Wave Life Sciences also furnished its updated corporate presentation and the related press release as exhibits to this report, while specifying that these materials are being furnished rather than filed for securities law purposes.
Wave Life Sciences is raising capital through an underwritten public offering of 15,789,475 ordinary shares at $19.00 per share, plus pre-funded warrants to purchase up to 2,631,578 shares at $18.9999 each, and 2,763,157 additional shares purchased by the underwriters.
The transaction is expected to generate approximately $402.5 million in gross proceeds before fees, with all securities sold by the company. Including these proceeds, Wave Life Sciences expects its cash and cash equivalents to fund operations into the third quarter of 2028 and anticipates having approximately 187,693,059 ordinary shares outstanding after closing.
Wave Life Sciences Ltd. furnished an updated corporate presentation for the investment community. The new presentation, dated November 17, 2025, provides business updates and is available in the Investors section of the company’s website. It is also included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings.
Wave Life Sciences Ltd. filed an 8-K announcing financial results for the quarter ended September 30, 2025. The accompanying press release was furnished as Exhibit 99.1 and incorporated by reference.
The company states the Item 2.02 information is being furnished and not deemed filed under the Exchange Act. Wave’s ordinary shares trade on The Nasdaq Global Market under the symbol WVE.
Wave Life Sciences filed an 8-K/A to correct a typographical error in Exhibit 99.1 of a prior 8-K and furnished the corrected press release. The company also hosted a Research Day webcast and issued a release summarizing key updates, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity. Certain information was furnished under Item 7.01 and incorporated by reference under Item 8.01.
Wave Life Sciences (WVE) filed an 8-K announcing a Research Day webcast held on October 29, 2025, and made the slide presentation available on its investor website. The company also furnished a press release summarizing highlights from the event, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity.
The materials are provided under Regulation FD as Item 7.01 information furnished, not filed, and thus are not subject to Section 18 liabilities. The press release (other than its second paragraph) is incorporated by reference into Item 8.01. Exhibit 99.1 contains the press release; the cover page interactive data file is included as Exhibit 104.
Wave Life Sciences Ltd. furnished an updated corporate presentation to the investment community. The presentation, dated September 24, 2025, provides updates and summaries of the company’s business and is available in the “For Investors & Media” section of its website and as Exhibit 99.1. The information is furnished under a regulation fair disclosure item and is not considered filed for liability purposes under the Exchange Act, unless specifically incorporated into another filing.
Wave Life Sciences reported that its drug candidate WVE-006 showed positive data in the ongoing Phase 1b/2a RestorAATion-2 study for alpha-1 antitrypsin deficiency (AATD). This is an early- to mid‑stage clinical trial, so positive results can be an important step toward later-stage development if they are confirmed over time.
The company also scheduled an investor conference call at 8:30 a.m. ET on September 3, 2025, to discuss the results and plans to share an investor slide presentation on its website. Most of the information in the related press release is being treated as supplemental disclosure rather than as part of its formal financial reporting.
Wave Life Sciences Ltd. shareholders at the Annual General Meeting on August 5, 2025 approved an amendment increasing the companys 2021 Equity Incentive Plan by 8,000,000 ordinary shares. A quorum of 145,170,578 of 159,227,061 eligible shares (91.17%) was present or represented by proxy. The equity plan amendment passed 105,936,049 for to 24,647,485 against.
Shareholders re-elected nine directors to serve until the 2026 meeting, re-appointed KPMG LLP as auditor with 144,541,282 votes in favor, approved non-employee director compensation and a general share allotment authorization, and supported annual advisory votes on executive compensation. Voting records show significant opposition on several proposals and nominees as reflected by multi-million vote totals against certain items.
Event: On August 5, 2025, Wave Life Sciences Ltd. (WVE) filed a Form 8-K disclosing an updated corporate presentation.
Details: The Company stated the presentation, which it uses to "provide updates and summaries of its business," is available in the "For Investors & Media" section of its website at http://ir.wavelifesciences.com/ and is furnished as Exhibit 99.1 to this Current Report. The disclosure is made under Item 7.01 (Regulation FD Disclosure) and expressly notes the presentation is furnished and not "filed" for purposes of Section 18 of the Exchange Act. The exhibits list also includes a Cover Page Interactive Data File (Exhibit 104). No financial statements, earnings data, material transactions, guidance, or additional substantive financial information are included. The report was signed by CFO Kyle Moran on August 5, 2025.